Cargando…

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma

ONC201 is an oral, small molecule selective antagonist of the G protein-coupled receptor DRD2 that causes p53-independent apoptosis in tumor cells via integrated stress response activation and Akt/ERK inactivation. We performed a Phase II study that enrolled 17 patients with recurrent, bevacizumab-n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arrillaga-Romany, Isabel, Chi, Andrew S., Allen, Joshua E., Oster, Wolfgang, Wen, Patrick Y., Batchelor, Tracy T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668041/ https://www.ncbi.nlm.nih.gov/pubmed/29108308 http://dx.doi.org/10.18632/oncotarget.17837

Ejemplares similares

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
por: Prabhu, Varun Vijay, et al.
Publicado: (2020)

Discovery and clinical introduction of first-in-class imipridone ONC201
por: Allen, Joshua E., et al.
Publicado: (2016)

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201
por: Allen, Joshua E., et al.
Publicado: (2021)

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
por: Stein, Mark N., et al.
Publicado: (2019)

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma
por: Tu, Yong-sheng, et al.
Publicado: (2017)

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors
por: Prabhu, Varun V., et al.
Publicado: (2017)

A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins
por: El-Soussi, Sarra, et al.
Publicado: (2021)

HGG-15. THE IMIPRIDONE ONC201 IN COMBINATION WITH THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD HAS A SYNERGISTIC EFFECT IN PRECLINICAL MODELS OF PHGGS AND DMGS
por: de la Nava, Daniel, et al.
Publicado: (2021)

MODL-06. PRECLINICAL EFFICACY OF THE IMIPRIDONE ONC-206 AGAINST MEDULLOBLASTOMA
por: Malhotra, Anshu, et al.
Publicado: (2020)

HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
por: Kawakibi, Abed Rahman, et al.
Publicado: (2020)

Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
por: Le Tourneau, C., et al.
Publicado: (2022)

Imipridone family on successful TRAIL
por: Anderson, Peter M., et al.
Publicado: (2017)

Phase I study of gemcitabine using a once every 2 weeks schedule.
por: Vermorken, J. B., et al.
Publicado: (1997)

Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia
por: Nii, Takenobu, et al.
Publicado: (2019)

CLRM-02 SINGLE CENTER EXPERIENCE OF DOPAMINE ANTAGONIST ONC-201 FOR RECURRENT H3K27M-MUTANT GLIOBLASTOMA IN ADULTS
por: Ekhator, Chukwuyem, et al.
Publicado: (2022)

TIPS-08 ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA
por: Arrillaga-Romany, Isabel, et al.
Publicado: (2023)

HGG-36. ONC201 TARGETING IN DIPG
por: Abuarqoub, Alqassem, et al.
Publicado: (2021)

Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
por: Macdougall, Iain C
Publicado: (2007)

ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro
por: Zhang, Yingao, et al.
Publicado: (2020)

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
por: Rovithi, Maria, et al.
Publicado: (2019)

Role of Dopamine Receptors in the Anticancer Activity of ONC201()()
por: Kline, Christina Leah B., et al.
Publicado: (2017)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016)

Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma
por: Pruss, Maximilian, et al.
Publicado: (2020)

Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor()
por: Hayes-Jordan, Andrea A., et al.
Publicado: (2018)

HGG-44. REVEALING VULNERABILITIES IN DIPG THROUGH ONC201
por: Stafford, James, et al.
Publicado: (2021)

An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study
por: Galle, Jan-Christoph, et al.
Publicado: (2012)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin
por: Menon, Nandini S., et al.
Publicado: (2022)

A Single-Center Experience of Dopamine Antagonist ONC201 for Recurrent Histone H3 Lysine 27-to-Methionine (H3K27M)-Mutant Glioblastoma in Adults
por: Ekhator, Chukwuyem, et al.
Publicado: (2022)

TIC10/ONC201: a bend in the road to clinical development
por: Greer, Yoshimi Endo, et al.
Publicado: (2015)

ONC201 kills breast cancer cells in vitro by targeting mitochondria
por: Greer, Yoshimi Endo, et al.
Publicado: (2018)

DIPG-57. TRANSCRIPTOMIC AND PROTEOMIC ANALYSES OF DIPG RESPONSE TO ONC201
por: Sridharan, Sreepradha, et al.
Publicado: (2020)

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
por: Kerbusch, T, et al.
Publicado: (2004)

Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype
por: Hu, Wen, et al.
Publicado: (2020)

Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate
por: Morrison, Laura, et al.
Publicado: (2023)

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours
por: Rasschaert, M, et al.
Publicado: (2007)

Which is the best schedule of autologous blood storage for pre-operative AIS patients? Every week or every 2 weeks
por: Tamai, Koji, et al.
Publicado: (2015)

Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial
por: Fountzilas, George, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_183ipif7kb5h3ap1ohrejaks22